Active Surveillance Is the Preferred Approach to Clinical Stage I Testicular Cancer
Cet article passe en revue les travaux récents justifiant le recours à une surveillance active chez les patients atteints d'un cancer du testicule de stade I
A simple framing statement is needed to consolidate decision making and guide management for the most common setting in testicular cancer.1 Clinical stage I (CSI) testicular cancer is, by far, the most prevalent presentation and now represents approximately 75% of the 8,500 new patients diagnosed with testicular cancer in the United States annually. In 2012, we saw emerging evidence that despite compelling cooperative group trials, institutional reports, and a proliferation of guidelines and recommendations, options for CSI testicular cancer were often misunderstood or misapplied, and in particular, active surveillance was underutilized...
Journal of Clinical Oncology , article en libre accès, 2013